Differences underlying EGFR and HER2 oncogene addiction

Por Faber, Anthony C., Wong, Kwok-Kin, Engelman, Jeffrey A.
Publicado em 2010

The BCL-2 family: key mediators of the apoptotic response to targeted anti-cancer therapeutics

Por Hata, Aaron N., Engelman, Jeffrey A., Faber, Anthony C.
Publicado no Cancer Discov (2015)

Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Por Ebi, Hiromichi, Faber, Anthony C, Engelman, Jeffrey A, Yano, Seiji
Publicado no Cancer Sci (2014)

Thematic Review Series: Sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a

Por Mukherjee, Purna, Faber, Anthony C., Shelton, Laura M., Baek, Rena C., Chiles, Thomas C., Seyfried, Thomas N.
Publicado em 2008

Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mutant lung cancer

Por Kitai, Hidenori, Ebi, Hiromichi, Tomida, Shuta, Floros, Konstantinos V., Kotani, Hiroshi, Adachi, Yuta, Oizumi, Satoshi, Nishimura, Masaharu, Faber, Anthony C., Yano, Seiji
Publicado no Cancer Discov (2016)

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

Por Guix, Marta, Faber, Anthony C., Wang, Shizhen Emily, Olivares, Maria Graciela, Song, Youngchul, Qu, Sherman, Rinehart, Cammie, Seidel, Brenda, Yee, Douglas, Arteaga, Carlos L., Engelman, Jeffrey A.
Publicado em 2008

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

Por Rothenberg, S Michael, Concannon, Kyle, Cullen, Sarah, Boulay, Gaylor, Turke, Alexa B, Faber, Anthony C, Lockerman, Elizabeth L, Rivera, Miguel N, Engelman, Jeffrey A, Maheswaran, Shyamala, Haber, Daniel A
Publicado no eLife (2015)

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

Por Ebi, Hiromichi, Costa, Carlotta, Faber, Anthony C., Nishtala, Madhuri, Kotani, Hiroshi, Juric, Dejan, Della Pelle, Patricia, Song, Youngchul, Yano, Seiji, Mino-Kenudson, Mari, Benes, Cyril H., Engelman, Jeffrey A.
Publicado em 2013

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

Por Faber, Anthony C., Li, Danan, Song, YoungChul, Liang, Mei-Chih, Yeap, Beow Y., Bronson, Roderick T., Lifshits, Eugene, Chen, Zhao, Maira, Sauveur-Michel, García-Echeverría, Carlos, Wong, Kwok-Kin, Engelman, Jeffrey A.
Publicado em 2009

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung cancers

Por Hata, Aaron N., Yeo, Alan, Faber, Anthony C., Lifshits, Eugene, Chen, Zhao, Cheng, Katherine A., Walton, Zandra, Sarosiek, Kristopher A., Letai, Anthony, Heist, Rebecca S., Mino-Kenudson, Mari, Wong, Kwok-Kin, Engelman, Jeffrey A.
Publicado em 2014

Measurement of PIP(3) Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

Por Costa, Carlotta, Ebi, Hiromichi, Martini, Miriam, Beausoleil, Sean A., Faber, Anthony C., Jakubik, Charles T., Huang, Alan, Wang, Youzhen, Nishtala, Madhuri, Hall, Ben, Rikova, Klarisa, Zhao, Jean, Hirsch, Emilio, Benes, Cyril H., Engelman, Jeffrey A.
Publicado no Cancer Cell (2014)

An ErbB3 antibody, MM-121, is active in cancers with ligand dependent activation

Por Schoeberl, Birgit, Faber, Anthony C., Li, Danan, Liang, Mei-Chih, Crosby, Katherine, Onsum, Matthew, Burenkova, Olga, Pace, Emily, Walton, Zandra, Nie, Lin, Fulgham, Aaron, Song, Youngchul, Nielsen, Ulrik B., Engelman, Jeffrey A., Wong, Kwok-Kin
Publicado em 2010

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer

Por Roper, Jatin, Sinnamon, Mark J., Coffee, Erin M., Belmont, Peter, Keung, Lily, Georgeon-Richard, Larissa, Wang, Wei Vivian, Faber, Anthony C., Yun, Jihye, Yilmaz, Omer H., Bronson, Roderick T., Martin, Eric S., Tsichlis, Philip N., Hung, Kenneth E.
Publicado em 2014

Concomitant BRAF and PI3K/mTOR Blockade is Required for Effective Treatment of BRAF(V600E) Colorectal Cancer

Por Coffee, Erin M., Faber, Anthony C., Roper, Jatin, Sinnamon, Mark J., Goel, Gautam, Keung, Lily, Wang, Wei Vivian, Vecchione, Loredana, de Vriendt, Veerle, Weinstein, Barbara J., Bronson, Roderick T., Tejpar, Sabine, Xavier, Ramnik J., Engelman, Jeffrey A., Martin, Eric S., Hung, Kenneth E.
Publicado em 2013

TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma

Por Corcoran, Ryan B., Rothenberg, Stephen Michael, Hata, Aaron N., Faber, Anthony C., Piris, Adriano, Nazarian, Rosalynn M., Brown, Ronald D., Godfrey, Jason T., Winokur, Daniel, Walsh, John, Mino-Kenudson, Mari, Maheswaran, Shyamala, Settleman, Jeffrey, Wargo, Jennifer A., Flaherty, Keith T., Haber, Daniel A., Engelman, Jeffrey A.
Publicado em 2013

BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors

Por Faber, Anthony, Corcoran, Ryan B., Ebi, Hiromichi, Sequist, Lecia V., Waltman, Belinda A., Chung, Euiheon, Incio, Joao, Digumarthy, Subba R., Pollack, Sarah F., Song, Youngchul, Muzikansky, Alona, Lifshits, Eugene, Roberge, Sylvie, Coffman, Erik J., Benes, Cyril, Gómez, Henry, Baselga, Jose, Arteaga, Carlos L., Rivera, Miguel N., Dias-Santagata, Dora, Jain, Rakesh K., Engelman, Jeffrey A.
Publicado em 2011

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

Por Corcoran, Ryan B., Cheng, Katherine A., Hata, Aaron N., Faber, Anthony C., Ebi, Hiromichi, Coffee, Erin M., Greninger, Patricia, Brown, Ronald D., Godfrey, Jason T., Cohoon, Travis J., Song, Youngchul, Lifshits, Eugene, Hung, Kenneth E., Shioda, Toshi, Dias-Santagata, Dora, Singh, Anurag, Settleman, Jeffrey, Benes, Cyril H., Mino-Kenudson, Mari, Wong, Kwok-Kin, Engelman, Jeffrey A.
Publicado em 2012

Activation of PI3K signaling in Merkel cell carcinoma

Por Nardi, Valentina, Song, Young Chul, Santamaria-Barria, Juan A., Cosper, Arjola K., Lam, Quynh, Faber, Anthony C., Boland, Genevieve M., Yeap, Beow Y., Bergethon, Kristin, Scialabba, Vanessa L., Tsao, Hensin, Settleman, Jeffrey, Ryan, David P., Borger, Darrell R., Bhan, Atul, Hoang, Mai P., Iafrate, Anthony J., Cusack, James C., Engelman, Jeffrey A., Dias-Santagata, Dora
Publicado em 2012

mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

Por Faber, Anthony C., Coffee, Erin M., Costa, Carlotta, Dastur, Anahita, Ebi, Hiromichi, Hata, Aaron N., Yeo, Alan T., Edelman, Elena J., Song, Youngchul, Tam, Ah Ting, Boisvert, Jessica L., Milano, Randy J., Roper, Jatin, Kodack, David P., Jain, Rakesh K., Corcoran, Ryan B., Rivera, Miguel N., Ramaswamy, Sridhar, Hung, Kenneth E., Benes, Cyril H., Engelman, Jeffrey A.
Publicado em 2013

Patient-derived Models of Acquired Resistance Can Identify Effective Drug Combinations for Cancer

Por Crystal, Adam S., Shaw, Alice T., Sequist, Lecia V., Friboulet, Luc, Niederst, Matthew J., Lockerman, Elizabeth L., Frias, Rosa L., Gainor, Justin F., Amzallag, Arnaud, Greninger, Patricia, Lee, Dana, Kalsy, Anuj, Gomez-Caraballo, Maria, Elamine, Leila, Howe, Emily, Hur, Wooyoung, Lifshits, Eugene, Robinson, Hayley E., Katayama, Ryohei, Faber, Anthony C., Awad, Mark M., Ramaswamy, Sridhar, Mino-Kenudson, Mari, Iafrate, A. John, Benes, Cyril H., Engelman, Jeffrey A.
Publicado no Science (2014)